The evolving clinical spectrum of neuromyelitis optica

The evolving clinical spectrum of neuromyelitis optica

Bibliographic Details
Main Authors:	Viegas, S, Weir, A, Esiri, M, Hart, Y, Newsom-Davis, J, Vincent, A, Palace, J
Format:	Conference item
Published:	2008

Similar Items

Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.
by: Viegas, S, et al.
Published: (2009)

NEUROMYELITIS OPTICA SPECTRUM AND RELATIONSHIP WITH AQUAPORIN-4 ANTIBODY DISEASE: THE OXFORD COHORT
by: Leite, M, et al.
Published: (2009)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
by: Collongues, N, et al.
Published: (2013)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
by: Matthews, L, et al.
Published: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
by: Matthews, L, et al.
Published: (2013)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
by: Kim, W, et al.
Published: (2012)

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
by: Nour, M, et al.
Published: (2014)

The borderland of neuromyelitis optica.
by: Matthews, L, et al.
Published: (2009)

Racial differences in neuromyelitis optica spectrum disorder
by: Kim, S, et al.
Published: (2018)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
by: Downer, J, et al.
Published: (2012)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?
by: Downer, J, et al.
Published: (2012)

Use of mitoxantrone in neuromyelitis optica.
by: Kitley, J, et al.
Published: (2011)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
by: Kitley, J, et al.
Published: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
by: Kitley, J, et al.
Published: (2013)

Alternative antigen targets in aquaporin-4 antibodynegative neuromyelitis optica spectrum disorders
by: Kitley, J, et al.
Published: (2013)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
by: Pittock, S, et al.
Published: (2019)

Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply.
by: Kitley, J, et al.
Published: (2014)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
by: Elsone, L, et al.
Published: (2012)

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
by: Nour, M, et al.
Published: (2015)

NEUROMYELITIS OPTICA SPECTRUM DISORDER AND CMV RETINITIS: A CASE REPORT
by: George, J, et al.
Published: (2012)

Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features.
by: Absoud, M, et al.
Published: (2014)

Magnetic resonance imaging in neuromyelitis optica.
by: Tackley, G, et al.
Published: (2014)

CAN MRI BE USED AS A DIAGNOSTIC TOOL IN NEUROMYELITIS OPTICA SPECTRUM DISORDER?
by: Matthews, L, et al.
Published: (2012)

NMO-IgG in the diagnosis of neuromyelitis optica.
by: Jarius, S, et al.
Published: (2007)

A practical guide to the treatment of neuromyelitis optica.
by: Palace, J, et al.
Published: (2012)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
by: Waters, P, et al.
Published: (2015)

Characterizing mortality in patients with AQP4‐Ab + neuromyelitis optica spectrum disorder
by: Francis, A, et al.
Published: (2024)

Pain in neuromyelitis optica spectrum disease: a cross-sectional study in an English cohort
by: Leonard, H, et al.
Published: (2012)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.
by: Kitley, J, et al.
Published: (2014)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
by: Kitley, J, et al.
Published: (2014)

Treatment of Neuromyelitis Optica: Review and Recommendations.
by: Kimbrough, D, et al.
Published: (2012)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
by: Fujihara, K, et al.
Published: (2014)

Aquaporin-4 Antibody Isoform Binding Specificity Does Not Explain Clinical Variations in Neuromyelitis Optica
by: Kitley, J, et al.
Published: (2013)

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
by: Paul, F, et al.
Published: (2007)

Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies A Comparative Study
by: Kitley, J, et al.
Published: (2014)

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
by: Kitley, J, et al.
Published: (2014)

Treatment of neuromyelitis optica: Review and recommendations
by: Kimbrough, D, et al.
Published: (2012)

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.
by: Saadoun, S, et al.
Published: (2010)

Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.
by: Leite, M, et al.
Published: (2012)

Seasonal pattern of variation in neuromyelitis optica relapses
by: Elsone, L, et al.
Published: (2012)